Charles River Laboratories International Stock News

Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.

CRL is a high-quality business that operates quietly and unnoticed in the background. It has consistently grown revenue, earnings and free cash flow over the years.

Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.

Charles River Laboratories International Inc. shares CRL, +0.89% slid 6% in premarket trade Wednesday, after the drug company issued a profit warning for the second quarter. The company is now expecte

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.

Charles River Laboratories International, Inc. (NYSE:CRL ) Q1 2022 Earnings Conference Call May 4, 2022 9:30 AM ET Company Participants Todd Spencer - VP, IR James Foster - Chairman, President and CEO

Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.

Charles River (CRL) delivered earnings and revenue surprises of 1.48% and 0.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.

Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.

Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.